Rx Statin "Black Box" Petition Could Affect OTC Switch Considerations
This article was originally published in The Tan Sheet
Executive Summary
The chances of cholesterol-lowering statins switching OTC would appear slim if FDA were to grant a Public Citizen Health Research Group petition requesting all such Rx drugs carry a "black box" warning about the risk of rhabdomyolysis.
You may also be interested in...
Pravachol Low Drug Interaction Profile Deemed Favorable During OTC Review
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, FDA advisory committee members suggested.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands